245 related articles for article (PubMed ID: 33782605)
21. SYK-CARD9 Signaling Axis Promotes Gut Fungi-Mediated Inflammasome Activation to Restrict Colitis and Colon Cancer.
Malik A; Sharma D; Malireddi RKS; Guy CS; Chang TC; Olsen SR; Neale G; Vogel P; Kanneganti TD
Immunity; 2018 Sep; 49(3):515-530.e5. PubMed ID: 30231985
[TBL] [Abstract][Full Text] [Related]
22. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
23. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
[TBL] [Abstract][Full Text] [Related]
24. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
Gururajan M; Dasu T; Shahidain S; Jennings CD; Robertson DA; Rangnekar VM; Bondada S
J Immunol; 2007 Jan; 178(1):111-21. PubMed ID: 17182546
[TBL] [Abstract][Full Text] [Related]
25. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Zhang Z; Cao C; Sun S; Xu Q
Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
[TBL] [Abstract][Full Text] [Related]
26. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
[TBL] [Abstract][Full Text] [Related]
27. CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease.
Gong W; Yu J; Zheng T; Liu P; Zhao F; Liu J; Hong Z; Ren H; Gu G; Wang G; Wu X; Zhao Y; Ren J
Clin Transl Med; 2021 Feb; 11(2):e339. PubMed ID: 33634985
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine Kinase SYK Licenses MyD88 Adaptor Protein to Instigate IL-1α-Mediated Inflammatory Disease.
Gurung P; Fan G; Lukens JR; Vogel P; Tonks NK; Kanneganti TD
Immunity; 2017 Apr; 46(4):635-648. PubMed ID: 28410990
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.
Novikov FN; Panova MV; Titov IY; Stroylov VS; Stroganov OV; Chilov GG
Sci Rep; 2021 Nov; 11(1):23120. PubMed ID: 34848799
[TBL] [Abstract][Full Text] [Related]
30. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
[TBL] [Abstract][Full Text] [Related]
31. Syk-MyD88 Axis Is a Critical Determinant of Inflammatory-Response in Activated Macrophages.
Yi YS; Kim HG; Kim JH; Yang WS; Kim E; Jeong D; Park JG; Aziz N; Kim S; Parameswaran N; Cho JY
Front Immunol; 2021; 12():767366. PubMed ID: 35003083
[TBL] [Abstract][Full Text] [Related]
32. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease.
Dierks C; Adrian F; Fisch P; Ma H; Maurer H; Herchenbach D; Forster CU; Sprissler C; Liu G; Rottmann S; Guo GR; Katja Z; Veelken H; Warmuth M
Cancer Res; 2010 Aug; 70(15):6193-204. PubMed ID: 20670954
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
34. Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Yu Y; Suryo Rahmanto Y; Shen YA; Ardighieri L; Davidson B; Gaillard S; Ayhan A; Shi X; Xuan J; Wang TL; Shih IM
EBioMedicine; 2019 Sep; 47():184-194. PubMed ID: 31492560
[TBL] [Abstract][Full Text] [Related]
35. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.
Rinaldi A; Ponzoni M; Uccella S; Rossi D; Gaidano G; Facchetti F; Pruneri G; Tibiletti MG; Capella C; Zucca E; Doglioni C; Catapano C; Bertoni F
Hematol Oncol; 2011 Sep; 29(3):164-6. PubMed ID: 21416481
[No Abstract] [Full Text] [Related]
36. A Mouse Model for the Study of SYK Function through Chemical Genetics Demonstrates SYK-Dependent Signaling through the B Cell Receptor, but Not TLR4.
Wang WH; Krisenko MO; Higgins RL; Morman RE; Geahlen RL
Immunohorizons; 2019 Jul; 3(7):254-261. PubMed ID: 31356155
[TBL] [Abstract][Full Text] [Related]
37. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
38. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis.
Clarke AS; Rousseau E; Wang K; Kim JY; Murray BP; Bannister R; Matzkies F; Currie KS; Di Paolo JA
Thromb Res; 2018 Oct; 170():109-118. PubMed ID: 30172129
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Benefits of Spleen Tyrosine Kinase Inhibitor Administration on Binge Drinking-Induced Alcoholic Liver Injury, Steatosis, and Inflammation in Mice.
Bukong TN; Iracheta-Vellve A; Gyongyosi B; Ambade A; Catalano D; Kodys K; Szabo G
Alcohol Clin Exp Res; 2016 Jul; 40(7):1524-30. PubMed ID: 27177528
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.
Bukong TN; Iracheta-Vellve A; Saha B; Ambade A; Satishchandran A; Gyongyosi B; Lowe P; Catalano D; Kodys K; Szabo G
Hepatology; 2016 Oct; 64(4):1057-71. PubMed ID: 27302565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
